NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective AgonistTOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei...
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY...
– Two Academic Powerhouses form Institut Pasteur-UCSF QBI Center of Excellence in Emerging Diseases with Planned Operations/Locations in San Francisco...
TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access...
WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel...
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor...
Yale Spinout Moves Closer Toward IND-enabling StudiesNEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in...
THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two...
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health,...
Study Design EnACT Phase 2 DesignTwo-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203 Mean...
U.S. Patent for Bioelectric Expression of Klotho, a Key Longevity and Disease-Fighting Protein Issued to Leonhardt Ventures U.S. Patent for...
Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL...
MacroMedics Product Shot MacroMedics mask being used in radiotherapy October 20, 2022 FDA 510(k) clearance for AI-enabled Philips MR for...
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics...
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of...
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,...
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein...
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma...
SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease...